Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price ...

Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), ...

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -43.75% and 1.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s rating is based on Apellis Pharmaceuticals’ strategic ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...